Apr 25, 2023 · While Novo Nordisk is probably the better weight-management stock, a more diverse product lineup and development pipeline make Eli Lilly the better overall pharmaceutical business.

Dec 26, 2024 · Both Lilly and Novo Nordisk are experiencing unprecedented growth thanks to their weight loss medications. However, Lilly also treats cancer, plaque psoriasis, Alzheimer's disease, eczema,...

Oct 16, 2024 · The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of notable wins have me thinking this lead will widen.

Aug 3, 2024 · Eli Lilly (LLY 2.45%) and Novo Nordisk (NVO 8.47%) are the two big names dominating the anti-obesity market today. They've been generating billions in revenue from their treatments, and...

Jan 3, 2024 · Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk and Eli Lilly—overwhelming...

Aug 21, 2024 · Novo Nordisk and Eli Lilly are expanding beyond obesity drugs, targeting new markets for long-term growth. Eli Lilly's stock shows stronger technical momentum, trading above key moving...

Aug 8, 2023 · Shares of pharmaceutical giant Eli Lilly skyrocketed to a record high on Tuesday, after the company reported a surge in sales of its diabetes and weight loss drug Mounjaro, while shares of...

Dec 4, 2024 · Eli Lilly revealed trial results that showed its obesity drug Zepbound was 47% more effective than Novo’s Wegovy in helping patients lose weight.

Eli Lilly stock and Novo Nordisk shares haven't had a smooth year, but events in the fourth quarter widened the gap between the weight-loss drugmakers.

Jan 31, 2025 · Compare Eli Lilly and Co LLY and Novo Nordisk NVO. Get comparison charts for tons of financial metrics!